UK regulator approves Lilly's Alzheimer's drug but 'too expensive' for wider use; Donanemab, given as an infusion every four weeks, has shown to slow down cognitive decline by 4-7 months in clinical studies.

Media contributions

• Title	UK regulator approves Lilly's Alzheimer's drug but 'too expensive' for wider use; Donanemab, given as an infusion every four weeks, has shown to slow down cognitive decline by 4-7 months in clinical studies.
  Media name/outlet	Financial Express
  Media type	Web
  Country/Territory	India
  Date	23/10/24
  Persons	Tara Spires-Jones